http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102195196-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-20034 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-20022 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10042 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10343 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-20032 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-20071 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-585 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-543 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5258 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5256 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0011 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-33 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-37 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-12 |
| filingDate | 2013-01-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-12-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-12-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-102195196-B1 |
| titleOfInvention | Polynucleotides for treating oncogenic viral polypeptide positive tumors |
| abstract | This document relates to polynucleotides encoding antigenic polypeptides that elicit an immune response against tumorigenic viral polypeptides. Also provided are compositions comprising a polynucleotide encoding an antigenic polypeptide and a method of using the same. In the methods provided, the virus may be a human papilloma virus. In some embodiments, a method of killing cells expressing a first oncogenic viral polypeptide in a subject is provided. The method comprises administering to a subject a sufficient amount of a composition to initiate an immune response against a first oncogenic viral peptide, wherein the composition comprises a pharmaceutically acceptable carrier and a polynucleotide provided herein, wherein the immune response Is effective in causing cytotoxic effects in cells. In some embodiments, the polynucleotide comprises a second nucleotide sequence encoding a second antigenic polypeptide. The first oncogenic viral polypeptide can be E6 and the second oncogenic viral polypeptide can be E7. |
| priorityDate | 2012-01-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 645.